PL397261A1 - Aktywowany polimer glikolu polialkilenowego, kompozycja i kompozycja farmaceutyczna oraz ich zastosowanie - Google Patents

Aktywowany polimer glikolu polialkilenowego, kompozycja i kompozycja farmaceutyczna oraz ich zastosowanie

Info

Publication number
PL397261A1
PL397261A1 PL397261A PL39726103A PL397261A1 PL 397261 A1 PL397261 A1 PL 397261A1 PL 397261 A PL397261 A PL 397261A PL 39726103 A PL39726103 A PL 39726103A PL 397261 A1 PL397261 A1 PL 397261A1
Authority
PL
Poland
Prior art keywords
composition
polyalkylene glycol
glycol polymer
pharmaceutical composition
activated polyalkylene
Prior art date
Application number
PL397261A
Other languages
English (en)
Polish (pl)
Inventor
Kochung Lin
R. Blake Pepinsky
Ling Ling Chen
Donna M. Hess
Edward Y. Lin
Russell C. Petter
Darren P. Baker
Original Assignee
Biogen Idec Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc. filed Critical Biogen Idec Ma Inc.
Publication of PL397261A1 publication Critical patent/PL397261A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C08G65/48—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
PL397261A 2002-01-18 2003-01-17 Aktywowany polimer glikolu polialkilenowego, kompozycja i kompozycja farmaceutyczna oraz ich zastosowanie PL397261A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34991702P 2002-01-18 2002-01-18

Publications (1)

Publication Number Publication Date
PL397261A1 true PL397261A1 (pl) 2012-03-26

Family

ID=27613339

Family Applications (2)

Application Number Title Priority Date Filing Date
PL397261A PL397261A1 (pl) 2002-01-18 2003-01-17 Aktywowany polimer glikolu polialkilenowego, kompozycja i kompozycja farmaceutyczna oraz ich zastosowanie
PL372728A PL213322B1 (pl) 2002-01-18 2003-01-17 Kompozycja farmaceutyczna zawierajaca polimer glikolu polialkilenowego skoniugowany z biologicznie aktywnym zwiazkiem lub jego prekursorem oraz jej zastosowania

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL372728A PL213322B1 (pl) 2002-01-18 2003-01-17 Kompozycja farmaceutyczna zawierajaca polimer glikolu polialkilenowego skoniugowany z biologicznie aktywnym zwiazkiem lub jego prekursorem oraz jej zastosowania

Country Status (35)

Country Link
US (2) US8017733B2 (enFirst)
EP (3) EP3025726B1 (enFirst)
JP (5) JP2005526151A (enFirst)
KR (1) KR100964411B1 (enFirst)
CN (2) CN101700401B (enFirst)
AU (1) AU2003210564B2 (enFirst)
BE (1) BE2016C040I2 (enFirst)
BG (1) BG66525B1 (enFirst)
BR (1) BRPI0306993B8 (enFirst)
CA (4) CA2473526C (enFirst)
CY (3) CY1117349T1 (enFirst)
CZ (1) CZ2004877A3 (enFirst)
DK (2) DK3025726T3 (enFirst)
EA (2) EA011829B1 (enFirst)
EE (1) EE05509B1 (enFirst)
ES (2) ES2566797T3 (enFirst)
FR (1) FR16C0034I2 (enFirst)
GE (2) GEP20064024B (enFirst)
HU (4) HUE047557T2 (enFirst)
IL (1) IL163006A (enFirst)
IS (1) IS2989B (enFirst)
LU (1) LU93162I2 (enFirst)
ME (2) ME00239B (enFirst)
MX (1) MXPA04006855A (enFirst)
NL (1) NL300826I2 (enFirst)
NO (4) NO339857B1 (enFirst)
NZ (1) NZ534708A (enFirst)
PL (2) PL397261A1 (enFirst)
PT (1) PT3025726T (enFirst)
RS (1) RS55578B1 (enFirst)
SI (2) SI3025726T1 (enFirst)
SK (1) SK3102004A3 (enFirst)
UA (1) UA82184C2 (enFirst)
WO (1) WO2003061577A2 (enFirst)
ZA (1) ZA200406555B (enFirst)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150246097A9 (en) * 2002-01-18 2015-09-03 Biogen Idec Ma Inc. Polyalkylene Polymer Compounds and Uses Thereof
EE05509B1 (et) 2002-01-18 2012-02-15 Biogen@Idec@Ma@Inc Aktiveeritud polalkleenglkoolpolmeer ja seda sisaldavad kompositsioonid
PL375883A1 (en) 2002-09-09 2005-12-12 Nektar Therapeutics Al, Corporation Water-soluble polymer alkanals
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
PL396711A1 (pl) * 2002-12-26 2011-12-19 Mountain View Pharmaceuticals, Inc. Koniugaty polimerów z cytokinami, chemokinami, czynnikami wzrostu, hormonami polipeptydowymi i ich antagonistami, kompozycja farmaceutyczna i sposób zapobiegania, diagnozowania lub leczenia
EP1667708B9 (en) * 2002-12-26 2012-10-31 Mountain View Pharmaceuticals, Inc. POLYETHYLENE GLYCOL CONJUGATES OF INTERFERON-BETA-1b WITH ENHANCED IN VITRO BIOLOGICAL POTENCY
CN100343304C (zh) 2002-12-31 2007-10-17 尼克塔治疗亚拉巴马公司 水解稳定的马来酰亚胺封端的聚合物
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
ES2379466T3 (es) 2003-06-26 2012-04-26 Psivida Us, Inc. Sistema de suministro de fármacos de liberación sostenida bioerosionables
ES2315680T3 (es) 2003-06-26 2009-04-01 Psivida Inc. Sistema de distribucion de farmacos de gelificacion in situ.
EP1758583A2 (en) * 2004-05-31 2007-03-07 Ranbaxy Laboratories Limited Arylpiperazine derivatives useful as adrenergic receptor antagonists
CA2591233C (en) 2004-12-21 2014-10-07 Nektar Therapeutics Al, Corporation Stabilized polymeric thiol reagents
WO2006130553A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors
SG196786A1 (en) 2005-07-08 2014-02-13 Elan Pharm Inc Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds
JP2009538338A (ja) * 2006-05-22 2009-11-05 イーラン ファーマスーティカルズ、インコーポレイテッド 治療用、農業用及び食品添加用化合物のポリマー複合体の調製
US20100222546A1 (en) * 2006-11-28 2010-09-02 David Crich Methods for the preparation of functionalized peptides, proteins and carbohydrates and their conjugates
CA2693616A1 (en) * 2007-07-11 2009-01-15 Enzon Pharmaceuticals, Inc. Polymeric drug delivery system containing a multi-substituted aromatic moiety
WO2009009716A1 (en) * 2007-07-11 2009-01-15 Enzon Pharmaceuticals, Inc. Polymeric drug delivery systems containing an aromatic allylic acid
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
JP2011522834A (ja) * 2008-06-05 2011-08-04 ザイモジェネティクス リミテッド ライアビリティ カンパニー Ｃ型肝炎の治療のためのペグ化ｉｉｉ型インターフェロンの使用
CN102131844B (zh) * 2008-07-31 2016-03-02 药华医药股份有限公司 肽-聚合物缀合物
GB0823309D0 (en) 2008-12-19 2009-01-28 Univ Bath Functionalising reagents and their uses
US20120072207A1 (en) 2009-06-02 2012-03-22 Panasonic Corporation Down-mixing device, encoder, and method therefor
UA109646C2 (uk) * 2009-12-10 2015-09-25 Терапевтичне застосування кон'югатів білка з полімером
US20130225789A1 (en) * 2012-02-29 2013-08-29 Yi Sun Polyethylene Glycol Having Hetero Multiple Functional Groups
US8993614B2 (en) 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
KR101475630B1 (ko) * 2013-05-31 2014-12-22 동국대학교 산학협력단 포도근 추출물 또는 이의 분획물을 유효성분으로 포함하는 c형 간염의 예방 또는 치료용 조성물
US11759500B2 (en) * 2014-07-24 2023-09-19 Abion Inc. PEGylated interferon-beta variant
HRP20201725T1 (hr) * 2014-08-19 2021-03-05 Biogen Ma Inc. Postupak pegilacije
GB201419108D0 (en) 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
FI3215193T3 (fi) 2014-11-06 2023-12-28 Pharmaessentia Corp Pegyloidun interferonin annostusohjelma
EP3421442B1 (en) * 2017-06-28 2020-08-05 Construction Research & Technology GmbH Dispersant for inorganic particles
US11472894B2 (en) 2018-07-23 2022-10-18 Carnegie Mellon University Enzyme-assisted ATRP procedures
WO2020028715A1 (en) 2018-08-01 2020-02-06 Russell Alan J Amino-reactive positively charged atrp initiators that maintain their positive charge during synthesis of biomacro-initiators
CN109232898A (zh) * 2018-08-02 2019-01-18 张玲 一种具有抗凝血功能的聚酰亚胺新材料的制备方法
CN111534458B (zh) * 2020-04-13 2022-01-14 浙江工业大学 无色杆菌tbc-1及其在降解1,3,6,8-四溴咔唑中的应用
CN113716982B (zh) * 2021-08-24 2022-05-06 重庆云瑞肥业有限公司 一种食品垃圾回收用发酵制肥装置

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
DE3262575D1 (en) 1981-12-23 1985-04-18 Schering Corp Stabilised interferon formulations and their preparation
WO1985003934A1 (fr) * 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Proteine modifiee chimiquement et son procede de preparation
GB8334102D0 (en) * 1983-12-21 1984-02-01 Searle & Co Interferons with cysteine pattern
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
WO1987000056A1 (en) 1985-06-26 1987-01-15 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US4894226A (en) * 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5135919A (en) 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5286637A (en) * 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
WO1993012145A1 (en) * 1991-12-19 1993-06-24 Baylor College Of Medicine Pva or peg conjugates of peptides for epitope-specific immunosuppression
ZA933926B (en) * 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5874075A (en) * 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
HUT75533A (en) * 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
CA2206852A1 (en) * 1994-12-07 1996-06-13 Novo Nordisk A/S Polypeptide with reduced allergenicity
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
NZ322686A (en) * 1995-10-19 2000-01-28 Univ Washington Discrete-length polyethene glycols
US5702717A (en) * 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
JP2001508783A (ja) 1997-01-29 2001-07-03 ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー Ｐｅｇ化法
IL131730A (en) 1997-03-05 2004-06-20 Univ Washington Screening methods to identify factors that selectively inhibit hepatitis C virus replication
US5990237A (en) * 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US7642323B2 (en) * 1997-11-06 2010-01-05 Nektar Therapeutics Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6448369B1 (en) * 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
JP4465109B2 (ja) * 1997-12-17 2010-05-19 エンゾン ファーマシューティカルズ，インコーポレーテッド アミノ及びヒドロキシル含有生物活性剤のポリマープロドラッグ
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
DK1061954T3 (da) * 1998-03-12 2004-10-18 Nektar Therapeutics Al Corp Polyethylenglycolderivater med proximale reaktive grupper
PL193352B1 (pl) 1998-04-28 2007-02-28 Applied Research Systems Koniugat poliol-interferon ß, sposób jego wytwarzania i jego zastosowanie oraz kompozycja farmaceutyczna
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
EP1121156B1 (en) * 1998-10-16 2006-02-22 Biogen Idec MA Inc. Polymer conjugates of interferon beta- 1a and their uses
JP2003503367A (ja) * 1999-06-11 2003-01-28 シアウォーター・コーポレイション キトサンとポリ（エチレングリコール）または関連ポリマーから得られるヒドロゲル
SK2942002A3 (en) 1999-08-27 2002-08-06 Maxygen Aps A conjugate exhibiting interferon beta, a nucleotide sequence, an expressing vector, a host cell containing such a nucleotide sequence, method for the preparation thereof, pharmaceutical composition containing the same and its use
US7144574B2 (en) * 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
DE60026073T2 (de) 1999-12-22 2006-09-28 Nektar Therapeutics Al, Corp., Huntsville Sterisch gehinderte derivate von wasserlöslichen polymeren
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
EP1324779B1 (en) * 2000-09-29 2011-07-20 Schering Corporation Pegylated interleukin-10
TW593427B (en) * 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
US7053150B2 (en) * 2000-12-18 2006-05-30 Nektar Therapeutics Al, Corporation Segmented polymers and their conjugates
EE05537B1 (et) * 2001-02-01 2012-04-16 Biogen, Inc. Neublastiini polmeerkonjugaadid ja meetodid nende kasutamiseks
CZ20032526A3 (cs) 2001-02-27 2003-12-17 Maxygen Aps Nové molekuly podobné interferonu beta
US7009033B2 (en) * 2001-07-02 2006-03-07 Polymer Source Inc. Heterofunctional polyethylene glycol and polyethylene oxide, process for their manufacture
SI2939696T1 (sl) * 2001-10-18 2016-06-30 Nektar Therapeutics Polimerni konjugati opioidnih antagonistov
EP1453859A2 (en) * 2001-11-20 2004-09-08 Pharmacia Corporation Chemically-modified human growth hormone conjugates
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) * 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
EP1507755A4 (en) * 2001-12-11 2006-05-17 Sun Bio Inc NOVEL MONOFUNCTIONAL POLYETHYLENE GLYCOL ALDEHYDES
KR100488351B1 (ko) * 2001-12-11 2005-05-11 선바이오(주) 신규한 폴리에틸렌글리콜-프로피온알데히드 유도체
US7041855B2 (en) * 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
EE05509B1 (et) 2002-01-18 2012-02-15 Biogen@Idec@Ma@Inc Aktiveeritud polalkleenglkoolpolmeer ja seda sisaldavad kompositsioonid
PL375883A1 (en) 2002-09-09 2005-12-12 Nektar Therapeutics Al, Corporation Water-soluble polymer alkanals
EP1667708B9 (en) * 2002-12-26 2012-10-31 Mountain View Pharmaceuticals, Inc. POLYETHYLENE GLYCOL CONJUGATES OF INTERFERON-BETA-1b WITH ENHANCED IN VITRO BIOLOGICAL POTENCY
US20110165122A1 (en) * 2009-11-10 2011-07-07 The Regents Of The University Of California Method for targeted and sustained antiviral therapy

Also Published As

Publication number Publication date
KR20040081463A (ko) 2004-09-21
MXPA04006855A (es) 2005-04-19
FR16C0034I1 (enFirst) 2016-09-23
JP2009235409A (ja) 2009-10-15
EE200400105A (et) 2004-12-15
CN1630530A (zh) 2005-06-22
DK1476181T3 (en) 2016-05-23
KR100964411B1 (ko) 2010-06-15
BR0306993A (pt) 2005-09-06
CA2840490C (en) 2017-02-28
EP3025726A1 (en) 2016-06-01
JP6030717B2 (ja) 2016-11-24
CY2016027I2 (el) 2017-06-28
JP5275125B2 (ja) 2013-08-28
CA2473526C (en) 2013-10-22
US20120014916A1 (en) 2012-01-19
NO2026002I1 (no) 2026-01-13
BRPI0306993B1 (pt) 2020-03-10
EA009783B1 (ru) 2008-04-28
CZ2004877A3 (cs) 2004-12-15
CN101700401B (zh) 2013-08-14
HK1143553A1 (zh) 2011-01-07
ME00239B (me) 2011-05-10
ZA200406555B (en) 2005-11-30
NL300826I2 (enFirst) 2017-03-16
PT3025726T (pt) 2020-01-09
BRPI0306993B8 (pt) 2021-05-25
MEP35608A (hr) 2011-02-10
NZ534708A (en) 2007-05-31
JP2013136756A (ja) 2013-07-11
HUE028163T2 (en) 2016-11-28
JP2012255156A (ja) 2012-12-27
US8524660B2 (en) 2013-09-03
CA2473526A1 (en) 2003-07-31
EE05509B1 (et) 2012-02-15
HU230473B1 (hu) 2016-07-28
IS7353A (is) 2004-07-15
NO344612B1 (no) 2020-02-10
DK3025726T3 (da) 2019-12-09
NO339857B1 (no) 2017-02-06
UA82184C2 (uk) 2008-03-25
HUP0500457A2 (hu) 2005-08-29
GEP20074024B (en) 2007-01-10
HUE047557T2 (hu) 2020-04-28
EP1476181B1 (en) 2016-03-23
HUS1600035I1 (hu) 2016-10-28
EP1476181A2 (en) 2004-11-17
CY1117349T1 (el) 2017-04-26
NO2017013I2 (no) 2018-08-20
WO2003061577A8 (en) 2008-11-20
PL372728A1 (en) 2005-08-08
HUP0500457A3 (en) 2012-09-28
GEP20064024B (en) 2007-01-10
ES2566797T3 (es) 2016-04-15
US8017733B2 (en) 2011-09-13
EA200400962A1 (ru) 2005-06-30
CN101700401A (zh) 2010-05-05
CY1122841T1 (el) 2021-10-29
BG108839A (bg) 2005-04-30
EP3669887A1 (en) 2020-06-24
HK1224185A1 (en) 2017-08-18
IS2989B (is) 2017-11-15
NO20043422L (no) 2004-10-11
EP1476181A4 (en) 2008-11-19
AU2003210564B2 (en) 2008-10-23
JP2005526151A (ja) 2005-09-02
SK3102004A3 (sk) 2005-01-03
CA2952488C (en) 2019-05-07
RS63504A (sr) 2007-02-05
CA2840490A1 (en) 2003-07-31
ES2774801T3 (es) 2020-07-22
BG66525B1 (bg) 2016-04-28
CA2753899C (en) 2014-03-25
WO2003061577A3 (en) 2003-10-02
NO20151082A1 (no) 2015-08-26
IL163006A (en) 2011-01-31
HK1072721A1 (zh) 2005-09-09
CA2952488A1 (en) 2003-07-31
RS55578B1 (sr) 2017-06-30
SI1476181T1 (sl) 2016-10-28
WO2003061577A2 (en) 2003-07-31
JP2016014022A (ja) 2016-01-28
LU93162I2 (fr) 2016-10-03
PL213322B1 (pl) 2013-02-28
FR16C0034I2 (fr) 2019-10-04
BE2016C040I2 (enFirst) 2022-05-17
CA2753899A1 (en) 2003-07-31
EA011829B1 (ru) 2009-06-30
CY2016027I1 (el) 2017-06-28
NO2017013I1 (no) 2017-04-10
EP3025726B1 (en) 2019-11-20
EA200701386A1 (ru) 2007-10-26
SI3025726T1 (sl) 2020-03-31
US20050107277A1 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
PL397261A1 (pl) Aktywowany polimer glikolu polialkilenowego, kompozycja i kompozycja farmaceutyczna oraz ich zastosowanie
DK1721623T3 (da) Absorberende polymersammensætninger, medicinske artikler og fremgangsmåder
ATE401800T1 (de) Hochintensive süssstoffzusammensetzung und deren abgabe
EP1928930A4 (en) POLYALKYLENE GLYCOL MONOMER, POLYALKYLENE GLYCOL POLYMER CONTAINING THE SAME AND APPLICATION THEREOF
DE60316445D1 (de) Funktionalisiertes polymer und verbesserte vulkanisate daraus
EP1807436A4 (en) HETEROBIFUNCTIONAL POLY (ETHYLENE GLYCOL) AND USES THEREOF
EP1621569A4 (en) Polyethylene Glycol / polycation BLOCK COPOLYMER
DE60107941D1 (de) Blockcopolymerkautschuk, harzmodifizierer und harzzusammensetzung
DE602004021904D1 (de) Gyraseinhibitoren und deren verwendungen
DE60333218D1 (de) Polycarbonatcopolymer, harzzusammensetzung und formkörper
DE60331324D1 (de) Polycarbonatharzzusammensetzung und formkörper
DE60208177D1 (de) Propylenpolymerzusammensetzung, formkörper und polyolefincopolymer
EP1589071A4 (en) POLYETHEROL POLYOL COMPOSITION AND USE THEREOF
DK1587478T3 (da) Farmaceutisk sammensætning
DK1670769T3 (da) Benzimidazol-derivater, sammensætninger indeholdende disse, fremstilling deraf og anvendelser deraf
PL394604A1 (pl) Pochodna winyloazacykloalkanowa, jej zastosowanie oraz kompozycja farmaceutyczna
IL174479A (en) The derivatives of myastrin, pharmaceutical preparations containing them and their uses
DE60137941D1 (de) Polymerzusammensetzung
DE60323993D1 (de) Embran aus poly(m-phenylenisophthal-amid)
DE60120930D1 (de) Neues ethylencopolymer und dessen verwendungen
DE60329614D1 (de) Polymerzusammensetzung sowie diese enthaltende darreichungsformen
DE60230349D1 (de) Verbesserte Polymerzusammensetzung
ATE417048T1 (de) N-ä3-(3-substituierte pyrazoloä1,5-aüpyrimidin-7- yl)phenylü-sulfonamide, und zusammensetzungen, und damit in zusammenhang stehende verfahren
DE502004004912D1 (de) Polyethylenglykol und dessen herstellung
BR0308687B1 (pt) polìmero de poli(estireno-butadieno-estireno), e, composição adesiva termorreversìvel.